GLUCOVANCE
Patients should be informed of the potential risks and benefits of GLUCOVANCE
and of alternative modes of therapy. They should also be informed about
the importance of adherence to dietary instructions, of a regular exercise
program, and of regular testing of blood glucose, glycosylated hemoglobin, renal function, and hematologic parameters.
The risks of lactic acidosis associated with metformin therapy, its symptoms,
and conditions that predispose to its development, as noted in the WARNINGS
and PRECAUTIONS sections, should be explained to patients. Patients should
be advised to discontinue GLUCOVANCE immediately and to promptly notify their
health practitioner if unexplained hyperventilation, myalgia, malaise, unusual somnolence,
or other nonspecific symptoms occur. Once a patient is stabilized on any dose
level of
GLUCOVANCE, gastrointestinal symptoms, which are common during initiation of
metformin therapy, are unlikely to be drug related. Later occurrence of gastrointestinal
symptoms could be due to lactic acidosis or other serious disease.
The risks of hypoglycemia, its symptoms and treatment, and conditions that
predispose to its development should be explained to patients and responsible family members.
Patients should be counseled against excessive alcohol intake, either acute
or chronic, while receiving GLUCOVANCE. (See Patient Information Printed Below.)
Glucovance
Pregnancy
Metabolism and elimination
Patients with type 2 diabetes
Hypoglycemia
Mechanism of action
Metformin hydrochloride
Information for patients
Drug interactions
Overdosage
Glipizide (glucotrol)
Drugs without prescription
Online pharmacy - Med RX Pharmacy.